Skip to main content
. 2021 Jul 29;13(15):3830. doi: 10.3390/cancers13153830
3D Three-dimensional
ANOVA Analysis Of Variance
Anti-CTLA4 Anti-Cytotoxic T-Lymphocyte-associated Protein 4
Anti-PD1 Anti-Programmed Cell Death 1
BMI Body-Mass-Index
BOR Best Overall Response
CB Clinical Benefit
CR Complete Response
CT Computed Tomography
DFS Disease Free Survival
FDG-PET/CT 18F-2-Fluoro-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomography
GCP Good Clinical Practice
GE General Electric
h Hour
ICI Immune Checkpoint Inhibitors
IQR Interquartile Range
kV Kilovolt
LDH Lactate Dehydrogenase
mA Milliampere
mg/dL Milligram/Deciliter
mL Milliliter
MSS Melanoma Specific Survival
MTV Metabolic Tumor Volume
OSEM Ordered Subset Expectation Maximization
PD Progressive Disease
PET Positron Emission Tomography
PFS Progression Free Survival
PR Partial Response
S100 Calcium-binding protein B
SD Stable Disease
SUV Standardized Uptake Value
TLG Total Lesion Glycolysis
TOF Time-of-Flight
TP Time Point
VOI Volume of Interest